In vivo tau imaging in Alzheimer's disease and other dementias
Grant number: 1044361 | Funding period: 2013 - 2015
Alteration of the normal protein tau leads to its deposition inside the brain cells leading to their death. These deposits have been well characterized and they are associated with cognitive impairment. We propose to study tau deposits in vivo in humans using positron emission tomography (PET) and assess its association with cognition and other signs of neurodegeneration
Related publications (11)
Comparison of F-18-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL (R) approaches: Validation against histopathology
Vincent Dore, Santiago Bullich, Christopher C Rowe, Pierrick Bourgeat, Salamata Konate, Osama Sabri, Andrew W Stephens, Henryk Barthel, Jurgen Fripp, Colin L Masters, Ludger Dinkelborg, Olivier Salvado, Victor L Villemagne, Susan De Santi
INTRODUCTION: 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recru..
Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions
Victor L Villemagne, Vincent Dore, Samantha C Burnham, Colin L Masters, Christopher C Rowe
Most neurodegenerative disorders are associated with aggregated protein deposits. In the case of Alzheimer disease (AD), extracell..
F-18-Florbetaben PET beta-amyloid binding expressed in Centiloids
Christopher C Rowe, Vincent Dore, Gareth Jones, David Baxendale, Rachel S Mulligan, Santiago Bullich, Andrew W Stephens, Susan De Santi, Colin L Masters, Ludger Dinkelborg, Victor L Villemagne
PURPOSE: The Centiloid (CL) method enables quantitative values from Aβ-amyloid (Aβ) imaging to be expressed in a universal unit pr..
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using F-18-THK5105 PET
Nobuyuki Okamura, Shozo Furumoto, Michelle T Fodero-Tavoletti, Rachel S Mulligan, Ryuichi Harada, Paul Yates, Svetlana Pejoska, Yukitsuka Kudo, Colin L Masters, Kazuhiko Yanai, Christopher C Rowe, Victor L Villemagne
Non-invasive imaging of tau pathology in the living brain would be useful for accurately diagnosing Alzheimer's disease, tracking ..
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease
Victor L Villemagne, Shozo Furumoto, Michelle T Fodero-Tavoletti, Rachel S Mulligan, John Hodges, Ryuichi Harada, Paul Yates, Olivier Piguet, Svetlana Pejoska, Vincent Dore, Kazuhiko Yanai, Colin L Masters, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura
PURPOSE: Diagnosis of tauopathies such as Alzheimer's disease (AD) still relies on post-mortem examination of the human brain. A n..
Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies
Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura, Victor L Villemagne
INTRODUCTION: The introduction of tau imaging agents such as (18)F-THK523 offers new hope for the in vivo assessment of tau deposi..